Thyrocare Technologies Limited has received a tax demand notice from the Income Tax Department, requiring the diagnostic services company to pay ₹2,02,82,260 for Assessment Year 2024-25. The company disclosed this development through a regulatory filing under SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.

Notice Details and Timeline

The Income Tax Department issued the Notice of Demand under Section 156 of the Income-tax Act, 1961, dated March 27, 2026. Thyrocare Technologies received this notice on March 28, 2026, from the Assessment Unit of the Income Tax Department.

Financial Impact Assessment

According to the company's disclosure, there is no material impact on the financials, operations, or other activities of Thyrocare Technologies, except for the amount mentioned in the notice. The financial exposure of ₹2,02,82,260 may become payable to the authorities only if the company's submissions are not accepted by the Income Tax Department.

Company's Response Strategy

Thyrocare Technologies has indicated that it considers the demand specified in the notice as litigative in nature. The company plans to contest the demand before the appropriate authorities within the stipulated timelines as provided under the law.

The company's planned actions include:

• Evaluating the matter thoroughly
• Submitting an appropriate response to the tax authorities
• Filing a reply or appeal before the appropriate authority within prescribed timelines
• Contesting the demand through proper legal channels

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has also disseminated this information on its official website at investor.thyrocare.com to ensure transparency with stakeholders.

Brijesh Kumar, Company Secretary and Compliance Officer of Thyrocare Technologies Limited, signed the regulatory filing on March 29, 2026. The company has confirmed that no penalties, restrictions, or sanctions have been imposed as part of this communication, and no aberrations or non-compliances were specifically identified by the authorities in the notice.

Thyrocare Technologies Limited has completed the allotment of 3,624 equity shares under its Employee Stock Option Scheme on March 02, 2026. The allotment was approved by the company's Nomination & Remuneration Committee following the exercise of stock options by eligible grantees.

Share Allotment Details

The newly issued equity shares carry a face value of Rs. 10 each and will rank pari passu in all respects with the company's existing equity shares. This means the new shares will have equal rights and privileges as the current shareholding, including voting rights and dividend entitlements.

Impact on Share Capital

The allotment has resulted in an increase in the company's issued, subscribed and paid-up equity share capital:

The total increase in paid-up capital amounts to Rs. 36,240, representing the face value of the 3,624 newly allotted shares.

Regulatory Compliance and Next Steps

Thyrocare Technologies is currently in the process of applying for listing and trading approval of these newly allotted shares with the stock exchanges, specifically the National Stock Exchange of India Limited and BSE Limited. The company is also completing other necessary regulatory procedures as required.

Disclosure and Transparency

In line with regulatory requirements under Regulation 30, the company has made these disclosures available on its official website at investor.thyrocare.com/announcements/. The announcement was signed by Brijesh Kumar, Company Secretary and Compliance Officer, ensuring proper corporate governance protocols were followed.

This Employee Stock Option Scheme allotment reflects the company's commitment to employee participation in its growth and aligns with standard corporate practices for talent retention and motivation.